University will not provide any other form of compensation to you if you are injured. 
You may call 619-534-4520 for more information about this or to report research- 
related problems. 
Your participation in this study is entirely voluntary. You may refuse to participate or 
withdraw from the study at any time and for any reason without jeopardizing your 
future health care in any way at this institution. 
Because only a relatively small number of cells compared to the total number of cells in 
your body will be transferred back to you in this study, it is not known if you yourself 
will benefit. However, the knowledge gained from this study may benefit others in the 
future. 
There will be no added costs to patients participating in this study. This study will not 
pay for routine medical care. 
Alternative Therapies 
Neither HIV infection nor AIDS can be cured with presently known treatments. 
Alternative treatments available to you that may have some beneficial effects are 
medicines such as zidovudine (AZT), didanosine (ddl) and zalcitabine (ddC). Medicines 
(such as antibiotics), surgery or radiation therapy can be used to treat some 
complications of HIV infection. All of the above treatments, however, can and will be used 
if they are indicated for you according to standard clinical practice during this study- 
they will not interfere with ribozyme gene therapy. In other words, ribozyme gene 
therapy will be used in addition to these other established methods of treatment. You 
should also know that other experimental treatments for HIV are being investigated 
elsewhere and you can be referred to physicians who are conducting such trials. At some 
later time, should new alternatives for treatment of HIV become available, they will be 
discussed with you and offered to you. You also have the option to receive no treatment at 
this time. 
Confidentiality 
Every attempt will be made to preserve strict confidentiality and privacy throughout the 
study. When results of a study like this are reported in medical journals or at meetings 
the patients taking part are never identified. Research records will be kept confidential 
to the extent provided by law and are made available for review by the Food and Drug 
Administration or other authorized users, only under the guidelines established by the 
Federal Privacy Act. A qualified representative of the National Institutes of Health may 
inspect patient and study records. 
If you are female and capable of child-bearing, a sample of urine will be collected before 
the study is begun in order to be sure as possible that you are not pregnant. Both men and 
women who participate must agree to use an effective contraception method (such as 
condoms, the pill, diaphragm, or intrauterine device) to prevent reproduction for the 
duration of the study since it is possible that the treatment being tested could cause harm 
to an unborn child. Whether or not they also use a method such as the pill or diaphragm 
to ensure prevention of pregnancy, all people with HIV infection should always use a 
condom during sex to prevent transmission of HIV. 
Recombinant DNA Research, Volume 18 
[403] 
